BP435

萘普生

British Pharmacopoeia (BP) Reference Standard

• 别名: (S)-(+)-2-(6-甲氧基-2-萘基)丙酸
• 线性分子式: CH₃OC₁₀H₆CH(CH₃)CO₂H
• CAS号: 22204-53-1
• 分子量: 230.26
• Beilstein: 3591068
• EC號碼: 244-838-7
• MDL號碼: MFCD00010500
• 分類程式碼代碼: 41116107
• NACRES: NA.24

属性

• 等級: pharmaceutical primary standard
• API 家族: naproxen
• 形狀: powder
• 儲存期限: limited shelf life, expiry date on the label
• 製造商／商標名: BP
• mp: 152-154 °C (lit.)
• 應用: pharmaceutical; pharmaceutical small molecule
• 格式: neat
• 儲存溫度: 2-8°C
• SMILES 字串: COc1ccc2cc(ccc2c1)[C@H](C)C(O)=O
• InChI: 1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1
• InChI 密鑰: CMWTZPSULFXXJA-VIFPVBQESA-N
• 基因資訊: human ... PTGS1(5742) , PTGS2(5743)

说明

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Naproxen BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.

Also used in monographs such as:

Naproxen Gastro-resistant Tablets

Naproxen Oral Suspension

Naproxen Tablets

生化／生理作用

非选择性环加氧酶(COX-1 和 COX-2)抑制剂。

包裝

Unit quantity: 100 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

其他說明

Sales restrictions may apply.

安全信息

• 象形圖: GHS08,GHS07,GHS09
• 訊號詞: Warning
• 危險聲明: H302,H315,H319,H335,H361fd,H411
• 防範說明: P202 - P273 - P301 + P312 - P302 + P352 - P305 + P351 + P338 - P308 + P313
• 危險分類: Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3
• 標靶器官: Respiratory system
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3